Last reviewed · How we verify
Sigma-Tau Research, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PLC | PLC | phase 3 | PI3K inhibitor | PI3K | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Addpharma Inc. · 1 shared drug class
- Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Amorphical Ltd. · 1 shared drug class
- Angitia Incorporated Limited · 1 shared drug class
- Applied Biology, Inc. · 1 shared drug class
- Aptarion Biotech AG · 1 shared drug class
- AB Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sigma-Tau Research, Inc.:
- Sigma-Tau Research, Inc. pipeline updates — RSS
- Sigma-Tau Research, Inc. pipeline updates — Atom
- Sigma-Tau Research, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sigma-Tau Research, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sigma-tau-research-inc. Accessed 2026-05-16.